Baxter International
BAX

$35.51

1.2%

Market Cap: 18.1B

About: Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

Employees: 60,000

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

0

News positive %

of 11 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

65% more call options, than puts

Call options by funds: $212M | Put options by funds: $129M

38% more funds holding in top 10

Funds holding in top 10: 8 [Q4 2023] → 11 (+3) [Q1 2024]

13% more first-time investments, than exits

New positions opened: 110 | Existing positions closed: 97

8% more capital invested

Capital invested by funds: $17.7B [Q4 2023] → $19.2B (+$1.46B) [Q1 2024]

1% more funds holding

Funds holding: 884 [Q4 2023] → 897 (+13) [Q1 2024]

6% less repeat investments, than reductions

Existing positions increased: 297 | Existing positions reduced: 316

1.98% less ownership

Funds ownership: 90.29% [Q4 2023] → 88.31% (-1.98%) [Q1 2024]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$30

16%

downside

Avg. target

$41

16%

upside

High target

$54

52%

upside

10 analyst ratings

2 positive

20%

7 neutral

70%

1 negative

10%

Morgan Stanley Patrick Wood	16%downside $30	Underweight Downgraded	15 Jul 2024
Citigroup Joanne Wuensch	4%upside $37	Neutral Maintained	10 Jul 2024
Evercore ISI Group Vijay Kumar	27%upside $45	Outperform Maintained	2 Jul 2024
Goldman Sachs David Roman	1%upside $36	Neutral Initiated	30 May 2024
Citigroup Joanne Wuensch	7%upside $38	Neutral Maintained	22 May 2024

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about BAX published over the past 30 days

Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I898552708 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c.

Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors

Baxter Declares Quarterly Dividend

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diag.

Baxter Declares Quarterly Dividend

Baxter: Why Investors Should Take Advantage Of The Low Valuation

Baxter has been a poor performer over the last year. The stock now trades with an extremely low valuation relative to the stock's historical performance. Recently, the company raised guidance, which points to double-digit earnings growth. Analysts seem to believe this growth is sustainable.

Baxter: Why Investors Should Take Advantage Of The Low Valuation

Schaeffers Research

Baxter International Stock Downgraded on Margin Concerns

Shares of Baxter International Inc (NYSE:BAX) are down 2.9% at $34.28, after a downgrade from Morgan Stanley to "underweight" from "equal weight," with a price-target cut to $30 from $39.

Baxter International Stock Downgraded on Margin Concerns

AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Monday.

AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Zacks Investment Research

Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?

Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.

Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?

Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its 2023 Corporate Responsibility Report. The annual report showcases Baxter's dedication to making a meaningful difference in global healthcare and reporting with transparency on the environmental, social and governance topics most important to its stakeholders. “Baxter employees across the globe are connected by our shared commitment to doing business the right way and continually.

Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact

Zacks Investment Research

Should Value Investors Buy Baxter International (BAX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Baxter International (BAX) Stock?

3 Bargain Bin Stocks with Millionaire-Maker Potential

There are three main drivers of a stock's return: growth, the change in price-to-earnings (P/E) multiple and capital return. While investors often focus on the growth angle, an upward rating in multiple can also be a significant return driver for bargain stocks.

3 Bargain Bin Stocks with Millionaire-Maker Potential

Zacks Investment Research

Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall

Shares of Baxter International BAX have gained 2.8% since Jun 26, after the company announced the recall of its Life2000 Ventilation System. Though the share price had declined following the news, it recovered following reports of potential discussion on divestment of BAX's kidney care segment.

Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall

See News Rankings